FEMSelect

Company Overview

Snapshot

Founded in October 2012 by Boaz Harari and Prof. Menahem Neuman, FEMSelect operates with 11–50 employees. The company has raised $16.89 million across 7 funding rounds from 14 investors. In May 2024, FEMSelect secured convertible debt funding, with Robin Hood Ventures participating.

Business overview

FEMSelect develops EnPlace, a minimally invasive and mesh-free system for pelvic floor ligament fixation. This technology, designed to be introduced through the vaginal wall and secured to the pelvic floor ligament, provides stabilization for pelvic organ prolapse repair. The company serves the healthcare industry, specifically targeting doctors, surgeons, and hospitals with its medical device solutions in gynecology and women's health.

Strategic signal

In November 2021, FEMSelect announced CMS reimbursement for its innovative minimally invasive approach to pelvic organ prolapse repair. This development is a significant market validation for the company's EnPlace system, signaling to investors a clear pathway for broader adoption and revenue generation within the US healthcare system by addressing a critical aspect of patient access and affordability.

Company Intelligence Q&A

What is FEMSelect's core product?

FEMSelect's core product is EnPlace, a minimally invasive and mesh-free system designed for pelvic floor ligament fixation, which is used in the treatment of pelvic organ prolapse.

When was FEMSelect founded and by whom?

FEMSelect was founded in October 2012 by Boaz Harari and Prof. Menahem Neuman.

Has FEMSelect received any recent funding?

In May 2024, FEMSelect secured convertible debt funding, with Robin Hood Ventures participating.

What significant regulatory milestones has FEMSelect achieved?

FEMSelect's EnPlace device is FDA cleared and CE marked, indicating compliance with regulatory standards for medical devices in the US and Europe.

What was a key strategic development for FEMSelect in late 2021?

In November 2021, FEMSelect announced that its innovative minimally invasive approach to pelvic organ prolapse repair procedure received CMS reimbursement, which is crucial for market access and adoption.